previous serious infections, recurrent infections, or demyelinating disease. Switch to an IL-17i biologic over adding MTX to an IL-12/23i biologic (PICO 37). Very low Conditional recommendation based on very-low-quality evidence; may consider adding MTX in patients with only partial response to the current therapy or in those who potentially have not had enough time to adequately respond. * Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome